论文部分内容阅读
目的评价替吉奥(S-1)联合顺铂治疗进展期胃癌的近期疗效及安全性。方法 56例进展期胃癌患者分为治疗组和对照组,各28例。治疗组方案为S-1 60 mg bid,d1~d21;顺铂静脉滴注60 mg·m-2,d1~d3,4周为1个周期。对照组方案为静脉滴注奥沙利铂125 mg·m-2,d1;静脉滴注替加氟600mg·m-2,d1~d5;静脉滴注亚叶酸钙120 mg·m-2,d1~d5,3周为1个周期。3个周期后评价2组疗效及不良反应。结果治疗组和对照组的客观有效率分别为75.0%和42.9%,差异有统计学意义(P<0.05);治疗组Ⅲ~Ⅳ级不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论 S-1联合顺铂化疗方案一线治疗进展期胃癌的近期疗效较好,不良反应可以耐受。
Objective To evaluate the short-term efficacy and safety of tegaserod (S-1) combined with cisplatin in the treatment of advanced gastric cancer. Methods 56 patients with advanced gastric cancer were divided into treatment group and control group, 28 cases in each. Treatment group S-1 60 mg bid, d1 ~ d21; cisplatin intravenous infusion of 60 mg · m-2, d1 ~ d3, 4 weeks for a cycle. In the control group, oxaliplatin 125 mg · m-2, d1 was given intravenously; tegafur 600 mg · m-2, d1 ~ d5 were given intravenously; leucovorin 120 mg · m- ~ d5, 3 weeks for a cycle. Three cycles after the evaluation of two groups of efficacy and adverse reactions. Results The objective and effective rates of the treatment group and the control group were 75.0% and 42.9%, respectively, with significant difference (P <0.05). The incidence of grade Ⅲ-Ⅳ adverse reactions in the treatment group was significantly lower than that in the control group (P <0.05). Conclusion S-1 combined with cisplatin chemotherapy in the first-line treatment of advanced gastric cancer better efficacy, adverse reactions can be tolerated.